News, Events and Updates

Oct 31

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Aug 6

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

May 9

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

Dec 19, 2023

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP)

Stay Connected